Therapeutic Target-Humanized Mice
Cre/Dre-Driver Mice
Immunodeficient NMG Mice
Strain Name：SD-Slc22a1em1Smoc Strain State：Embryo cryopreservation | Cat. NO.：NR-KO-190009
Exon 2-3 of Slc22a1(Oct1) gene was deleted to generate Slc22a1(Oct1) knockout rat.
Strain Name：SD-Abcc2em1Smoc Strain State：Repository Live | Cat. NO.：NR-KO-200002
Exon 4-6 of Abcc2 gene was deleted to generate Abcc2 knockout rat.
microRNA (miRNA) microRNA mouse models Nobel Prize microRNA discovery genetically engineered mice miRNA in gene regulation miRNA therapeutics miRNA in cancer research customized mouse models contract research organization (CRO) preclinical drug discovery
The 2024 Nobel Prize in Physiology or Medicine awarded to Victor Ambros and Gary Ruvkun for their discovery of microRNA (miRNA) highlights its revolutionary role in gene regulation and disease treatment. This article explores miRNA's impact on neuroscience, cancer, and cardiovascular research. GenoBioTX offers advanced microRNA mouse models and customized genetic solutions, empowering researchers with essential tools to drive innovation in miRNA studies and therapeutic developments.
Antibody-Drug Conjugates ADC Development Preclinical Models Targeted Cancer Therapies GenoBioTX ADC Webinar Biopharma Research Oncology Biochemistry Cancer Treatment Preclinical Evaluation Monoclonal Antibodies Small Molecule Drugs
Join us for a webinar on June 26th, 2024, exploring the development and preclinical evaluation of Antibody-Drug Conjugates (ADCs). Learn from Dr. Hua Wei, VP of the Industrial Clients Department at GenoBioTX, about ADC components, mechanisms, historical evolution, and future directions.
Cancer therapy advancements In vivo tumor models Preclinical cancer research Drug development in oncology Gene-modified cell lines Immuno-oncology Tumor modeling for drug discovery Cancer drug development Animal modeling services Cancer drug preclinical models
Join us for an insightful webinar exploring the critical role of in vivo tumor models in advancing cancer drug therapy. We will provide an overview of the diverse tumor models developed by our company, highlighting case studies demonstrating their effectiveness in preclinical cancer research. The session will delve into the comprehensive use of gene-modified cell lines and genetically modified spontaneous mouse models, showcasing their application in mimicking human cancer biology. We will conclude with a brief introduction to our company and our commitment to accelerating cancer drug development through innovative animal modeling services.
Bone metastasis cancer model Pain-related behavior assessment Cancer-induced bone pain Bone cancer pain models Mouse bone metastasis model Animal models in cancer research Cancer research services Bone metastasis in mice Pain management in cancer
We are excited to announce that GenoBioTX has launched a new service featuring mouse bone metastasis cancer models and pain-related behavior assessment, designed to support cancer research and pain management effectively.
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
U-HuDTMbase® is composed of more than 600 therapeutic target-humanized mouse models, including multiple background strains, and has covered almost all commonly studied areas, such as oncology, metabolism, immunity, inflammation and more.
Gene editing technology GenoBioTX seminar Genome editing platform Gene regulation Gene editing techniques Biotechnology seminar Preclinical research tools.
This seminar will introduce GenoBioTX’s gene editing platform and technology, highlighting how these techniques can enhance your research projects. We will cover the history of genome editing, provide an overview of GenoBioTX’s gene editing platform and technology, and present case studies that demonstrate how our gene editing techniques can facilitate research advancements.
Please fill in the order form and we will contact you within 2 working days.
